ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1374

Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival
Abstract Number: 1375

The Relative Burden of Fatigue Is Associated with High TSH/fT4 Ratio in Korean Patients with Primary Sjogren’s Syndrome
Abstract Number: 1376

SJOGRENSER Registry: Prospective Evaluation of a Cohort of Patients with Primary Sjögren’s Syndrome After 8 Years of Follow-up
Abstract Number: 1377

Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study
Abstract Number: 1378

The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study
Abstract Number: 1379

Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome
Abstract Number: 1380

Synergistic Dose Effects of Extra X Chromosome in Development of Sjogren’s Syndrome in Klinefelter and Triple X Syndromes
Abstract Number: 1381

Fatigue and Associated Factors in Patients with Primary Sjogren’s Syndrome Compared to Secondary Sjogren’s Syndrome
Abstract Number: 1382

Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome
Abstract Number: 1383

Long-term Association Between Physical Activity and Global Functioning in Patients with axSpA: Results of a 2 Year Prospective Study
Abstract Number: 1384

Functional Status by Sex and Socioeconomic Status in Axial Spondyloarthritis
Abstract Number: 1385

Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers
Abstract Number: 1386

Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
Abstract Number: 1387

Power Doppler Musculoskeletal Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis
Abstract Number: 1388

Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].